TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03877783

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: recommended modified pharmacological treatment
Description: Hyperglycemia: first metformin till target level of HbA1c 1) 53-58 mmol/mol for patients with ≤2 coexisting chronic illnesses or 2) 59-64 mmol/mol for those with established cardiovascular disease (CVD). We will recommend a second glucose-lowering drug when HbA1c is not achieved and which reduce CVD even when the participant does not have a manifest CVD.~Hypertension: will be treated to achieve a target level according to European guidelines. Start with a combination of a renin-angiotensin system (RAS)-blocker and a thiazide in low dose or a combination of a RAS-blocker a calcium channel blocker in low dose. If the target is not reached within 12 weeks additional drugs should be added.~Dyslipidemia: Patients with a CVD risk of 2-8% within 5 years should receive treatment with atorvastatin 10mg +ezetimib 10mg; CVD risk 8-20%, atorvastatin 20mg + ezetimib 10mg and CVD risk \> 20% atorvastatin 40-80mg +ezetimib 10mg.
Study: NCT03011047

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic trans-antral approach
Description: new surgical approach to repair the orbital floor fractures through the maxillary sinus

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: trans-orbital surgical approach
Description: through the lower eyelid below the eyelashes ,then down to bone the herniated orbital content will be reduced through this incision traditional surgical approach to repair orbital floor fractures
Study: NCT02170532

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levalbuterol
Description: 0.5 ml. levalbuterol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levalbuterol
Description: 0.5 ml. levalbuterol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline
Description: 0.5ml saline

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: levalbuterol MDI

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: levalbuterol MDI

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: levalbuterol MDI
Study: NCT03691818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X0002 Spray
Description: According to the different dose groups assigned, each knee joint was sprayed with 1, 2 or 4 sprays.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X0002 Spray
Description: According to the different dose groups assigned, each knee joint was sprayed with 1, 2 or 4 sprays.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X0002 Spray
Description: According to the different dose groups assigned, each knee joint was sprayed with 1, 2 or 4 sprays.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen Tablet
Description: Ibuprofen Tab 400mg, tid.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen Tablet
Description: Ibuprofen Tab 400mg, tid.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen Tablet
Description: Ibuprofen Tab 400mg, tid.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibuprofen Placebo Tab
Description: Ibuprofen Placebo Tab 400mg, tid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen Placebo Tab
Description: Ibuprofen Placebo Tab 400mg, tid.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibuprofen Placebo Tab
Description: Ibuprofen Placebo Tab 400mg, tid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen Placebo Tab
Description: Ibuprofen Placebo Tab 400mg, tid.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibuprofen Placebo Tab
Description: Ibuprofen Placebo Tab 400mg, tid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen Placebo Tab
Description: Ibuprofen Placebo Tab 400mg, tid.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: X0002 Placebo Spray
Description: According to the different dose groups assigned, each knee joint was sprayed with 1, 2 or 4 sprays.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: X0002 Placebo Spray
Description: According to the different dose groups assigned, each knee joint was sprayed with 1, 2 or 4 sprays.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: X0002 Placebo Spray
Description: According to the different dose groups assigned, each knee joint was sprayed with 1, 2 or 4 sprays.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: X0002 Placebo Spray
Description: According to the different dose groups assigned, each knee joint was sprayed with 1, 2 or 4 sprays.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: X0002 Placebo Spray
Description: According to the different dose groups assigned, each knee joint was sprayed with 1, 2 or 4 sprays.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: X0002 Placebo Spray
Description: According to the different dose groups assigned, each knee joint was sprayed with 1, 2 or 4 sprays.
Study: NCT01035437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPPH 2-1[1-hexyloxyethyl]-2-devinyl Pyropheophorbide-a)
Description: HPPH in D5W, 4.0 mg/m2 infused over 1 hour
Study: NCT01614054

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey of patient's smoking habits
Description: Nicotine replacement therapy (inhalers, patches, gum, lozenges) at the discretion of the health care provider
Study: NCT03600610

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: gadolinium-enhanced cardiac MRI
Description: cardiac magnetic resonance imaging with gadolinium injection used T1-Mapping

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: gadolinium-enhanced cardiac MRI
Description: cardiac magnetic resonance imaging with gadolinium injection used T1-Mapping
Study: NCT01645696

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BD CGM with Outer Layer
Description: continuous (every 2 minutes) subcutaneous glucose monitoring for 72 hours.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BD CGM without Outer Layer
Description: continuous (every 2 minutes) subcutaneous glucose monitoring over 72 hours.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic iPro2 Professional CGM
Description: continuous subcutaneous glucose monitoring for 72 hours
Study: NCT01031732

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MIS-2 THA
Description: MIS two-incision THA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MIS-WJ
Description: MIS-Watson Jones THA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MIS-AL THA
Description: Transgluteal approach

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MIS-PL THA
Description: Posterolateral approach
Study: NCT04245696

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermal Handpiece / SubQ Handpiece
Description: Bipolar radiofrequency (RF) travels from the RF generator, through the electrodes and into the dermal layers beneath the surface of the skin. The microneedles of the Dermal and SubQ cartridges coupled with thermal heat will stimulate neocollagenesis and neoelastosis, aiding in the reduction of submental laxity.
Study: NCT03888547

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occupational Therapy Health & Wellness Education
Description: The OT Health and Wellness Program will have four weeks of education and individual integration intervention modules. One of the investigators will lead each of these weekly modules under the direct supervision of the Principal Investigator. Investigators will be trained to provide the standardized educational module for each topic area and for using outcome measures. Each module will have an identified theme and information provided in each group will be education to topic, evidence based literature on intervention strategies, lifestyle, or environmental modifications that improve performance of daily activities that will last approximately 45 minutes. After, group sharing of ideas and individual identification of weekly goals for integration of 1-3 targeted interventions will occur and last approximately 30-45 minutes).
Study: NCT00528333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lintuzumab (SGN-33)
Description: 600 mg IV on days 1, 8, 15 and 22 of cycle 1 and days 1 and 15 of each subsequent 28-day cycle up to a maximum of 12 cycles.
Study: NCT03299946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 240mg intravenously every 2 weeks (days 14, 28, 42, and 56 for a total of four doses), in combination with Cabozantinib 40mg by mouth daily for 8 weeks.
Study: NCT00528333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose cytarabine
Description: 20 mg SC twice a day on days 1-10 of each 28 day cycle up to a maximum of 12 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose cytarabine
Description: 20 mg SC twice a day on days 1-10 of each 28 day cycle up to a maximum of 12 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: IV administration on days 1, 8, 15, and 22 of cycle 1 and days 1 and 15 of each subsequent 28-day cycle up to a maximum of 12 cycles
Study: NCT01348347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volasertib, low dose, d1q3w
Description: Patient to receive low dose of Volasertib IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volasertib, middle dose, d1q3w
Description: Patient to receive middle dose of Volasertib IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volasertib, high dose, d1q3w
Description: Patient to receive high dose of Volasertib IV
Study: NCT00748033

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reference catheter: LoFric PVC, Nelaton 40 cm, CH 12
Description: The subjects were first catheterized with this reference catheter.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reference catheter: LoFric PVC, Nelaton 40 cm, CH 12
Description: The subjects were first catheterized with this reference catheter.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LoFric POBE Hydro-Kit II, 5 seconds
Description: An unsalted LoFric POBE Hydro-Kit II, Nelaton 40 cm, CH 12 with sodium chloride in wetting solution, activation time 5 seconds

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LoFric POBE Hydro-Kit II, 5 seconds
Description: An unsalted LoFric POBE Hydro-Kit II, Nelaton 40 cm, CH 12 with sodium chloride in wetting solution, activation time 5 seconds

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LoFric POBE Hydro-Kit II, 24 hours
Description: An unsalted LoFric POBE Hydro-Kit II, Nelaton 40 cm, CH 12 with sodium chloride in wetting solution, activation time 24 hours

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LoFric POBE Hydro-Kit II, 24 hours
Description: An unsalted LoFric POBE Hydro-Kit II, Nelaton 40 cm, CH 12 with sodium chloride in wetting solution, activation time 24 hours
Study: NCT03038958

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isobaric 2-chloroprocaine
Description: intrathecal injection of 50 mg isobaric 2-Chloroprocaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric prilocaine
Description: intrathecal injection of 50 mg hyperbaric prilocaine 2%
Study: NCT04268810

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bladder instillations
Description: bladder instillations with either solution (DMSO or Uracyst)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bladder instillations
Description: bladder instillations with either solution (DMSO or Uracyst)
Study: NCT04702334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid
Description: After application of local anesthetic, removal of plaque and polishing of the tooth surfaces was performed followed by the local administration of hyaluronic acid gel for the test group . The tip of blunt application needle mounted on the syringe containing HA was delicately inserted in the pocket until resistance was felt. The injection was performed until the remnants started getting out of the pocket.This adjunctive treatment was performed at baseline and at the 3 months control.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocain
Description: After application of local anesthetic, removal of plaque and polishing of the tooth surfaces was performed followed by the local administration of anesthetic for the control group. The tip of blunt application needle mounted on the syringe containing HA was delicately inserted in the pocket until resistance was felt. The injection was performed until the remnants started getting out of the pocket.This adjunctive treatment was performed at baseline and at the 3 months control.
Study: NCT04566224

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Macintosh size 2 blade
Description: intubate with Macintosh size 2 blade

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh size 3 blade
Description: intubate with Macintosh size 3 blade
Study: NCT03407105

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MDX-010
Description: Specified dose on specified days
Study: NCT00722033

Intervention type: DRUG
Group type: OTHER
Intervention: 3 protocols of Indomethacin administration
Description: Indomethacin will consecutive be infused in 30, 60 and 120 minutes in each patient who requires it.
Study: NCT02763189

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expert mentoring
Description: Experts will provide personalized instructional review on how to use the new device for changing endotracheal tubes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-study
Description: All subjects will receive self-study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-study
Description: All subjects will receive self-study
Study: NCT01018186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate/GW642444
Description: Combination inhaled corticosteroid and long-acting beta2-agonist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate
Description: Inhaled corticosteroid
Study: NCT00530764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex Low Dose
Description: Range of 1 to 4 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 10.8mg THC and 10mg CBD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex Medium Dose
Description: Range of 6 to 10 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 27mg THC and 25mg CBD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex High Dose
Description: Range of 11 to 16 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 43.2mg THC and 40mg CBD.
Study: NCT03577353

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dual Task Walking (DTW)
Description: Each training session began with 8 min of general warm-up and 2 min walk around the gym. Then, for safety reasons, the participants were attached to a harness. The participants began walking slowly on the treadmill for 3 min. In the following phases the participants walked at the same speed, while training with 3 VR games. Each session lasted 3 min, and 3 min of single walking was performed between VR sessions. After the final VR session, 2 min of single-task walking was performed in order to allow for recovery. The time walked in each trial from the starting point to the destination was kept constant at 20 min.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Single-task Treadmill Walking (TMW)
Description: this intervention, participants performed 8 min of general warm-up and 2 min walk around the gym, and then continued to walk for another 20 min on the treadmill at a speed that was equivalent to the intensity of 60%-70% of their heart rate reserve.
Study: NCT01242306

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intracoronary infusion of acetylcholine
Description: Acetylcholine will be infused at a concentration of 140 microg/minute, over a period of 2 minutes, yielding estimated intracoronary concentrations of 10(-5)mol/L, with the assumption of a flow rate of 80mL/min). All infusions will be delivered at a constant rate using an infusion pump. Subsequently, in order to evaluate the endothelium-independent vasomotor response, 2mg of isosorbide dinitrate or bolus 250microg of nitroglycerine will be infused by intracoronary bolus in all subjects. The response to nitrate will be recorded 1 minute after the bolus. A 3-min period will be allowed to elapse between each drug infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intracoronary infusion of acetylcholine
Description: Acetylcholine will be infused at a concentration of 140 microg/minute, over a period of 2 minutes, yielding estimated intracoronary concentrations of 10(-5)mol/L, with the assumption of a flow rate of 80mL/min). All infusions will be delivered at a constant rate using an infusion pump. Subsequently, in order to evaluate the endothelium-independent vasomotor response, 2mg of isosorbide dinitrate or bolus 250microg of nitroglycerine will be infused by intracoronary bolus in all subjects. The response to nitrate will be recorded 1 minute after the bolus. A 3-min period will be allowed to elapse between each drug infusion.
Study: NCT02282800

Intervention type: GENETIC
Intervention: Vitamin D receptor
Description: 50-100mg gingival tissue samples were collected from both test and control group for immunohistochemical staining to assess the number of vitamin D receptors in nucleus as well cytoplasm and also for RNA isolation to check the presence of VDR gene.

Intervention type: GENETIC
Intervention: Vitamin D receptor
Description: 50-100mg gingival tissue samples were collected from both test and control group for immunohistochemical staining to assess the number of vitamin D receptors in nucleus as well cytoplasm and also for RNA isolation to check the presence of VDR gene.
Study: NCT02913430

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: 500mg IM Q28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: 20mg PO Qdaily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palbociclib
Description: Tamoxifen or Fulvestrant plus palbociclib125mg/day PO on a 21 days on/7 days off schedule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palbociclib
Description: Tamoxifen or Fulvestrant plus palbociclib125mg/day PO on a 21 days on/7 days off schedule
Study: NCT01280058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Wild-type Reovirus
Description: Given IV
Study: NCT03440723

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DilaCheck
Description: Measuring device for the measurement of cervical dilation

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cervical dilation examination
Description: Sterile vaginal examination using subjective methods for measurement of cervical dilation
Study: NCT04159987

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinraza intrathecal injection
Description: The aim is to monitor the evolution of the Motor Function Measure-32 for SMA type II adult patients treated with SPINRAZA® (Nusinersen).
Study: NCT02446704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Study: NCT04086368

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adolescent Lateral Entry Femoral Nail
Description: The use of an less invasive implant that has the same accuracy.
Study: NCT02170532

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: breath actuated nebulizer

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: breath actuated nebulizer
Study: NCT04086368

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pediatric LCP Hip Plate System
Description: Open approach to the femur where the osteotomy and osteofixation with plate and screws are preformed
Study: NCT00834470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine
Description: Ketamine 2mg/kg IV + Atropine 0.01mg/kg or Same volume of Normal saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atropine
Description: Ketamine 2mg/kg IV + Atropine 0.01mg/kg or Same volume of Normal saline
Study: NCT01466660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: afatinib once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gefitinib
Description: Gefitinib once daily
Study: NCT01318278

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dopamine
Description: dopamine at low/medium/and high dose (5, 10, 15, and 20 mcg/kg/min) given IV as a continuous infusion, titrated up for efficacy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arginine Vasopressin
Description: vasopressin at low/medium/and high dose (0.01, 0.02, 0.03, or 0.04 units/kg/hr) given IV as a continuous infusion, titrated up for efficacy
Study: NCT02966093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Participants will received lenvatinib 24 mg (two 10-mg capsules + one 4-mg capsule) orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity, withdrawal of consent, or study termination by sponsor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Participants will received lenvatinib 24 mg (two 10-mg capsules + one 4-mg capsule) orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity, withdrawal of consent, or study termination by sponsor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will received lenvatinib matched placebo (two 10-mg capsules + one 4-mg capsule) orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity, withdrawal of consent, or study termination by sponsor.
Study: NCT00849615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 50mg/m2 qd15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 2600mg/m2 qd15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85mg/m2 qd15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: folinic acid
Description: 200mg/m2 qd15